Celecoxib

This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition

Issued and maintained by the United States Pharmacopeial Convention (USP)

DOWNLOAD PDF HERE

C₁₇H₁₄F₃N₃O₂S    381.4 

4-[5-(4-Methylphenyl)-3-(triuoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 

p-[5-p-Tolyl-3-(triuoromethyl)pyrazol-1-yl]benzenesulfonamide CAS RN®: 169590-42-5; UNII: JCX84Q7J1L. 

1 DEFINITION 

Celecoxib contains NLT 98.0% and NMT 102.0% of C₁₇H₁₄F₃N₃O₂S, calculated on the anhydrous basis. 

2 IDENTIFICATION 

Change to read: 

A. Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197A, 197K or 197M (CN 1-May-2020) 

[Note—If the spectra obtained show differences, dissolve the substance to be examined and the Reference Standard separately in isopropyl alcohol, evaporate to dryness, and record the new spectra.] 

B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay. 

3 ASSAY 

Procedure 

Buffer: 2.7 g/L of monobasic potassium phosphate adjusted with phosphoric acid to a pH of 3.0 ± 0.2 Mobile phase: Methanol, acetonitrile, and Buffer (3:1:6) 

Diluent: Methanol and water (3:1) 

System suitability solution: 0.5 mg/mL of USP Celecoxib RS and 2.4 µg/mL each of USP Celecoxib Related Compound A RS and USP Celecoxib Related Compound B RS in Diluent 

Standard solution: 0.5 mg/mL of USP Celecoxib RS in Diluent 

Sample solution: 0.5 mg/mL of Celecoxib in Diluent 

Chromatographic system 

(See Chromatography 〈621〉, System Suitability.) 

Mode: LC 

Detector: UV 215 nm 

Column: 4.6-mm × 25-cm; 5-µm packing L11 

Column temperature: 60° 

Flow rate: 1.5 mL/min 

Injection size: 25 µL 

Run time: About 1.5 times the celecoxib peak elution 

System suitability 

Samples: System suitability solution and Standard solution 

Suitability requirements 

Resolution: NLT 1.8 between celecoxib related compound A and celecoxib and NLT 1.8 between celecoxib and celecoxib related compound B, System suitability solution 

Relative standard deviation: NMT 0.73%, Standard solution 

Analysis 

Samples: Standard solution and Sample solution 

Calculate the percentage of C₁₇H₁₄F₃N₃O₂S in the portion of Celecoxib taken: 

Result = (r_U/r_S) × (C_S/C_U) × 100 

r_U = peak response from the Sample solution 

r_S = peak response from the Standard solution

C_S = concentration of the Standard solution (mg/mL) 

C_U = concentration of the Sample solution (mg/mL) 

Acceptance criteria: 98.0%–102.0% on the anhydrous basis 

4 IMPURITIES 

Inorganic Impurities 

Residue on Ignition 〈281〉: NMT 0.2%, using a platinum crucible 

Organic Impurities 

Procedure 

Buffer, Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay. 

Standard solution: 0.5 µg/mL of USP Celecoxib RS in Diluent 

System suitability 

Samples: System suitability solution and Standard solution 

Suitability requirements 

Resolution: NLT 1.8 between celecoxib related compound A and celecoxib and NLT 1.8 between celecoxib and celecoxib related compound B, System suitability solution 

Signal-to-noise ratio: NLT 20, Standard solution 

Analysis 

Samples: Standard solution and Sample solution 

Calculate the percentage of each impurity in the portion of Celecoxib taken: 

Result = (r_U/r_S) × (C_S/C_U) × 100

r_U = peak response for each impurity in the Sample solution 

r_S = peak response of celecoxib in the Standard solution 

C_S = concentration of celecoxib in the Standard solution (mg/mL)  

C_U = concentration of Celecoxib in the Sample solution (mg/mL) 

Acceptance criteria 

Individual impurities: See Table 1. [Note—Disregard any impurity peak less than 0.05%.] 

Table 1 

^_a 4-[5-(3-Methylphenyl)-3-(triuoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. 

^b 4-[3-(4-Methylphenyl)-5-(triuoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. 

5 SPECIFIC TESTS 

Water Determination, Method I〈921〉: NMT 0.5%, using a 400-mg sample 

6 ADDITIONAL REQUIREMENTS 

Packaging and Storage: Preserve in tight containers, protected from light and moisture. Store at room temperature. USP Reference Standards 〈11〉 

USP Celecoxib RS 

p-[5-p-Tolyl-3-(triuoromethyl)pyrazol-1-yl]benzenesulfonamide. 

C₁₇H₁₄F₃N₃O₂S    381.4 

USP Celecoxib Related Compound A RS 

4-[5-(3-Methylphenyl)-3-(triuoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. 

C₁₇H₁₄F₃N₃O₂S      381.4 

USP Celecoxib Related Compound B RS 

4-[3-(4-Methylphenyl)-5-(triuoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. 

C₁₇H₁₄F₃N₃O₂S     381.4